Tokyo Tape
Sign in
← Carna Biosciences

Quarterly report · Q3

4572.TEDINET S100S238
Period2023-01-01 → 2023-09-30
Filed2023-11-08
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥711m2023-01-01 → 2023-09-30Cons.Net sales
Revenue¥1.4bn2022-01-01 → 2022-12-31Cons.Net sales (5-year summary)
Revenue¥1.1bn2022-01-01 → 2022-09-30Cons.Net sales
Operating income−¥1.2bn2023-01-01 → 2023-09-30Cons.Operating income
Operating income−¥754m2022-01-01 → 2022-09-30Cons.Operating income
Ordinary income−¥1.2bn2023-01-01 → 2023-09-30Cons.Ordinary income
Ordinary income−¥1.3bn2022-01-01 → 2022-12-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥736m2022-01-01 → 2022-09-30Cons.Ordinary income
Profit before tax−¥1.2bn2023-01-01 → 2023-09-30Cons.Income before income taxes
Profit before tax−¥779m2022-01-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)−¥1.2bn2023-01-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥1.3bn2022-01-01 → 2022-12-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥795m2022-01-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income−¥1.2bn2023-01-01 → 2023-09-30Cons.Profit loss
Net income−¥795m2022-01-01 → 2022-09-30Cons.Profit loss
Total assets¥4.2bnat 2023-09-30Cons.Assets
Total assets¥4.3bnat 2022-12-31Cons.Assets
Total assets¥4.5bnat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥376mat 2023-09-30Cons.Liabilities
Total liabilities¥625mat 2022-12-31Cons.Liabilities
Net assets / equity¥3.8bnat 2023-09-30Cons.Net assets
Net assets / equity¥3.6bnat 2022-12-31Cons.Net assets
Net assets / equity¥3.9bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥3.4bnat 2023-09-30Cons.Cash and deposits
Cash and deposits¥3.4bnat 2022-12-31Cons.Cash and deposits
EPS (basic)¥-73.742023-01-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-20.132023-07-01 → 2023-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-99.12022-01-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-58.562022-01-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-31.922022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio91.0%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio85.0%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio86.5%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 10
SegmentItemPeriodValue
jpcrp040300-q3r_E00987-000Drug Discovery Businessreportable segmentsegment profit2023-01-01 → 2023-09-30−¥1.4bn
jpcrp040300-q3r_E00987-000Drug Discovery Support Businessreportable segmentrevenue2023-01-01 → 2023-09-30¥711m
jpcrp040300-q3r_E00987-000Drug Discovery Support Businessreportable segmentrevenue external2023-01-01 → 2023-09-30¥711m
jpcrp040300-q3r_E00987-000Drug Discovery Support Businessreportable segmentsegment profit2023-01-01 → 2023-09-30¥218m
jpcrp040300-q3r_E00987-000Drug Discovery Businessreportable segmentrevenue2022-01-01 → 2022-09-30¥286m
jpcrp040300-q3r_E00987-000Drug Discovery Businessreportable segmentrevenue external2022-01-01 → 2022-09-30¥286m
jpcrp040300-q3r_E00987-000Drug Discovery Businessreportable segmentsegment profit2022-01-01 → 2022-09-30−¥1.1bn
jpcrp040300-q3r_E00987-000Drug Discovery Support Businessreportable segmentrevenue2022-01-01 → 2022-09-30¥810m
jpcrp040300-q3r_E00987-000Drug Discovery Support Businessreportable segmentrevenue external2022-01-01 → 2022-09-30¥810m
jpcrp040300-q3r_E00987-000Drug Discovery Support Businessreportable segmentsegment profit2022-01-01 → 2022-09-30¥336m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 306
ItemContextValueUnit
Interest expenses noePrior1YTDDuration4278000JPY
Interest expenses noeCurrentYTDDuration2387000JPY
Guarantee commission noePrior1YTDDuration735000JPY
Guarantee commission noeCurrentYTDDuration577000JPY
Stock issuance cost noePrior1YTDDuration1434000JPY
Stock issuance cost noeCurrentYTDDuration5219000JPY
Other noePrior1YTDDuration49000JPY
Other noeCurrentYTDDuration0JPY
Non operating expensesPrior1YTDDuration6498000JPY
Non operating expensesCurrentYTDDuration8185000JPY
Ordinary incomePrior1YTDDuration-735543000JPY
Ordinary incomeCurrentYTDDuration-1203335000JPY
Impairment loss elPrior1YTDDuration43062000JPY
Impairment loss elCurrentYTDDuration4562000JPY
Extraordinary lossPrior1YTDDuration43062000JPY
Extraordinary lossCurrentYTDDuration4562000JPY
Income before income taxesPrior1YTDDuration-778606000JPY
Income before income taxesCurrentYTDDuration-1207898000JPY
Income taxes currentPrior1YTDDuration16703000JPY
Income taxes currentCurrentYTDDuration22530000JPY
Income taxes deferredPrior1YTDDuration-91000JPY
Income taxes deferredCurrentYTDDuration-84000JPY
Income taxesPrior1YTDDuration16612000JPY
Income taxesCurrentYTDDuration22445000JPY
Profit lossPrior1YTDDuration-795218000JPY
Profit lossCurrentYTDDuration-1230344000JPY
Profit loss attributable to owners of parentPrior1YTDDuration-795218000JPY
Profit loss attributable to owners of parentCurrentYTDDuration-1230344000JPY
Profit lossPrior1YTDDuration-795218000JPY
Profit lossCurrentYTDDuration-1230344000JPY
Valuation difference on available for sale securities net of tax ociPrior1YTDDuration-1716000JPY
Valuation difference on available for sale securities net of tax ociCurrentYTDDuration-651000JPY
Deferred gains or losses on hedges net of tax ociPrior1YTDDuration30787000JPY
Deferred gains or losses on hedges net of tax ociCurrentYTDDuration-615000JPY
Foreign currency translation adjustment net of tax ociPrior1YTDDuration47369000JPY
Foreign currency translation adjustment net of tax ociCurrentYTDDuration35318000JPY
Other comprehensive incomePrior1YTDDuration76440000JPY
Other comprehensive incomeCurrentYTDDuration34051000JPY
Comprehensive incomePrior1YTDDuration-718777000JPY
Comprehensive incomeCurrentYTDDuration-1196293000JPY
Comprehensive income attributable to owners of the parentPrior1YTDDuration-718777000JPY
Comprehensive income attributable to owners of the parentCurrentYTDDuration-1196293000JPY
Comprehensive income attributable to non controlling interestsPrior1YTDDuration－JPY
Comprehensive income attributable to non controlling interestsCurrentYTDDuration－JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q3r_E00987-000DrugDiscoverySupportBusinessReportableSegmentsMember809562000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q3r_E00987-000DrugDiscoveryBusinessReportableSegmentsMember286045000JPY
Revenues from external customersPrior1YTDDuration1095607000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q3r_E00987-000DrugDiscoverySupportBusinessReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q3r_E00987-000DrugDiscoveryBusinessReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration－JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-12-31pass
balance sheet identityconsolidated 2023-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-01-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-01-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2022-12-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass